The targeting of STAT3, which is a player in TNBC proliferation and migration [33], may be another promising target in combination with immunotherapy, since it is dysregulated in both tumor and non-tumor cells in the tumor microenvironment [34]. This evidence concerns the gene STAT3 and neoplasm.